Literature DB >> 20189725

Immunohistochemical expression of Ki67, c-erbB-2, and c-kit antigens in benign and malignant pheochromocytoma.

Seyed Mohammad Tavangar1, Ali Shojaee, Hedieh Moradi Tabriz, Vahid Haghpanah, Bagher Larijani, Ramin Heshmat, Anahita Lashkari, Sima Azimi.   

Abstract

In this study, we evaluated the immunohistochemical expression and the possible advantages of Ki67 antigen, c-erbB-2, and c-kit proto-oncogenes in the differentiation between benign and malignant pheochromocytomas. Paraffin-embedded tissue blocks from 44 benign (35 adrenal and 9 extra-adrenal) and 11 malignant (9 adrenal and 2 extra-adrenal) cases of pheochromocytoma were selected for immunohistochemical staining using antibodies against Ki67, c-erbB-2, and c-kit antigens. We investigated the relationship between the expression of these antigens and age, gender, tumor size, histologic patterns and necrosis, as well as tumor behavior. The risk of malignancy was higher when tumor size was increased. We found out that more uncommon tissue patterns, such as small cell and spindle cell patterns, are mostly indicators of malignancy. There was a statistically significant relationship between Ki67- and c-erbB-2-positive staining of the tumor cells and the malignant behavior of the pheochromocytomas (p-value=0.000), while cytoplasmic c-kit staining did not show any correlation with tumor malignancy (p-value=0.087). We concluded that tumor size and the histomorphologic patterns (spindle cell and small round cell) are significantly associated with tumor behavior. In addition, Ki67 positivity and c-erbB-2 expression can be used as immunohistochemical markers for predicting the malignant behavior of pheochromocytoma. (c) 2010 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20189725     DOI: 10.1016/j.prp.2010.01.007

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  23 in total

1.  Malignant pheochromocytoma: new malignancy criteria.

Authors:  Pierre de Wailly; Luigi Oragano; Francois Radé; Anthony Beaulieu; Vincent Arnault; Pierre Levillain; Jean Louis Kraimps
Journal:  Langenbecks Arch Surg       Date:  2011-11-09       Impact factor: 3.445

2.  Overexpression of Bcl-2-associated death inhibits A549 cell growth in vitro and in vivo.

Authors:  Na Huang; Jing Zhu; Dan Liu; Ya-Lun Li; Bo-Jiang Chen; Yan-Qi He; Kun Liu; Xian-Ming Mo; Wei-Min Li
Journal:  Cancer Biother Radiopharm       Date:  2011-10-19       Impact factor: 3.099

Review 3.  Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment.

Authors:  Victoria L Martucci; Karel Pacak
Journal:  Curr Probl Cancer       Date:  2014-01-15       Impact factor: 3.187

Review 4.  Pheochromocytomas and paragangliomas: assessment of malignant potential.

Authors:  Tim I M Korevaar; Ashley B Grossman
Journal:  Endocrine       Date:  2011-10-25       Impact factor: 3.633

5.  FDG-PET/CT and FLT-PET/CT for differentiating between lipid-poor benign and malignant adrenal tumours.

Authors:  Masatoyo Nakajo; Megumi Jinguji; Yoshihiko Fukukura; Yoriko Kajiya; Atushi Tani; Masayuki Nakajo; Yoshiaki Nakabeppu; Hiroshi Arimura; Yoshihiko Nishio; Fumihiko Nakamura; Takashi Yoshiura
Journal:  Eur Radiol       Date:  2015-04-30       Impact factor: 5.315

6.  Malignant pheochromocytoma with lung metastasis after right adrenalectomy for pheochromocytoma eleven years ago.

Authors:  Won Suk Choi; Jong Yoon Park; Mee Sook Roh; Pil Jo Choi
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

Review 7.  Malignant pheochromocytomas and paragangliomas: a diagnostic challenge.

Authors:  Oliver Gimm; Catherine DeMicco; Aurel Perren; Francesco Giammarile; Martin K Walz; Laurent Brunaud
Journal:  Langenbecks Arch Surg       Date:  2011-11-29       Impact factor: 3.445

8.  Catecholamine-Synthesizing Enzymes in Pheochromocytoma and Extraadrenal Paraganglioma.

Authors:  Sachiko Konosu-Fukaya; Kei Omata; Yuta Tezuka; Yoshikiyo Ono; Yayoi Aoyama; Fumitoshi Satoh; Fumiyoshi Fujishima; Hironobu Sasano; Yasuhiro Nakamura
Journal:  Endocr Pathol       Date:  2018-12       Impact factor: 3.943

Review 9.  Metastatic paraganglioma.

Authors:  Stephanie M J Fliedner; Hendrik Lehnert; Karel Pacak
Journal:  Semin Oncol       Date:  2010-12       Impact factor: 4.929

Review 10.  Current and future therapeutic approaches for metastatic pheochromocytoma and paraganglioma: focus on SDHB tumors.

Authors:  J Matro; A Giubellino; K Pacak
Journal:  Horm Metab Res       Date:  2013-01-15       Impact factor: 2.936

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.